Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5281057
Max Phase: Preclinical
Molecular Formula: C39H63N17O11S4
Molecular Weight: 1074.31
Associated Items:
ID: ALA5281057
Max Phase: Preclinical
Molecular Formula: C39H63N17O11S4
Molecular Weight: 1074.31
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
Standard InChI: InChI=1S/C39H63N17O11S4/c1-3-17(2)29(38(67)55-26-15-69-68-12-23(30(43)59)52-36(26)65)56-33(62)21(6-7-27(41)57)50-32(61)20(5-4-8-47-39(44)45)49-34(63)22(9-18-11-46-16-48-18)51-35(64)25-14-71-70-13-24(37(66)54-25)53-31(60)19(40)10-28(42)58/h11,16-17,19-26,29H,3-10,12-15,40H2,1-2H3,(H2,41,57)(H2,42,58)(H2,43,59)(H,46,48)(H,49,63)(H,50,61)(H,51,64)(H,52,65)(H,53,60)(H,54,66)(H,55,67)(H,56,62)(H4,44,45,47)/t17-,19-,20-,21-,22-,23-,24-,25-,26-,29-/m0/s1
Standard InChI Key: NIJRCVCZMLKDMN-UTLFUYNOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1074.31 | Molecular Weight (Monoisotopic): 1073.3776 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Brust A, Croker DE, Colless B, Ragnarsson L, Andersson Å, Jain K, Garcia-Caraballo S, Castro J, Brierley SM, Alewood PF, Lewis RJ.. (2016) Conopeptide-Derived κ-Opioid Agonists (Conorphins): Potent, Selective, and Metabolic Stable Dynorphin A Mimetics with Antinociceptive Properties., 59 (6): [PMID:26859603] [10.1021/acs.jmedchem.5b00911] |
Source(1):